创新医疗最新公告：博灵脑机产品赛博灵科AC5已于2025年10月正式上市销售2025年共实现收入11.40万元

Core Viewpoint - The company has noted increased market attention on its brain-computer interface business, particularly through its subsidiary, Boling Brain Technology (Hangzhou) Co., Ltd, which was established in early 2021 and included in the consolidated financial statements in August 2025 [1] Group 1: Company Overview - Boling Brain Technology focuses on rehabilitation training for patients with cerebrovascular diseases, primarily targeting stroke and hemiplegia patients, both in medical institutions and at home [1] - The product "Cyberlink AC5" was officially launched in October 2025, generating revenue of 114,000 yuan in that year [1] - The "Cyberlink AM5" product has completed multi-center clinical trials but has not yet generated revenue as of 2025 [1] Group 2: Financial Performance - The operating losses for Boling Brain Technology were 6.60 million yuan in 2023 and 8.66 million yuan in 2024 [1]